Systemic Idiopathic Juvenile Arthritis - Pipeline Review, H2 2017

Publisher Name :
Date: 12-Sep-2017
No. of pages: 56
Inquire Before Buying

Systemic Idiopathic Juvenile Arthritis - Pipeline Review, H2 2017

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Systemic Idiopathic Juvenile Arthritis - Pipeline Review, H2 2017, provides an overview of the Systemic Idiopathic Juvenile Arthritis (Musculoskeletal Disorders) pipeline landscape.

Systemic onset juvenile idiopathic arthritis (also known as Systemic juvenile idiopathic arthritis (sJIA)) is a disorder featuring inflammation, characterized by high spiking fevers, salmon-colored rash that comes and goes, and arthritis. Symptoms are extreme fatigue accompanied by high fevers that rise daily to 102 F (39 C) or even higher and rapidly return to normal levels or below. Fever spikes often occur at approximately the same time every day. A faint salmon colored skin rash characteristically comes and goes and does not itch. Poor appetite, nausea, and weight loss are common. There is also commonly swelling of the lymph glands, enlargement of the spleen and liver, and sore throat. Some patients develop inflammation around the heart (pericarditis) and lungs (pleuritis), with occasional fluid accumulation around heart (pericardial effusion) and lungs (pleural effusion).

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Systemic Idiopathic Juvenile Arthritis - Pipeline Review, H2 2017, provides comprehensive information on the therapeutics under development for Systemic Idiopathic Juvenile Arthritis (Musculoskeletal Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Systemic Idiopathic Juvenile Arthritis (Musculoskeletal Disorders) pipeline guide also reviews of key players involved in therapeutic development for Systemic Idiopathic Juvenile Arthritis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Preclinical and Discovery stages are 2, 5 and 1 respectively.

Systemic Idiopathic Juvenile Arthritis (Musculoskeletal Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Systemic Idiopathic Juvenile Arthritis (Musculoskeletal Disorders).

- The pipeline guide reviews pipeline therapeutics for Systemic Idiopathic Juvenile Arthritis (Musculoskeletal Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.

- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

- The pipeline guide reviews key companies involved in Systemic Idiopathic Juvenile Arthritis (Musculoskeletal Disorders) therapeutics and enlists all their major and minor projects.

- The pipeline guide evaluates Systemic Idiopathic Juvenile Arthritis (Musculoskeletal Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

- The pipeline guide reviews latest news related to pipeline therapeutics for Systemic Idiopathic Juvenile Arthritis (Musculoskeletal Disorders)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

- Find and recognize significant and varied types of therapeutics under development for Systemic Idiopathic Juvenile Arthritis (Musculoskeletal Disorders).

- Classify potential new clients or partners in the target demographic.

- Develop tactical initiatives by understanding the focus areas of leading companies.

- Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.

- Formulate corrective measures for pipeline projects by understanding Systemic Idiopathic Juvenile Arthritis (Musculoskeletal Disorders) pipeline depth and focus of Indication therapeutics.

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Systemic Idiopathic Juvenile Arthritis - Pipeline Review, H2 2017

Table of Contents
List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Systemic Idiopathic Juvenile Arthritis - Overview
Systemic Idiopathic Juvenile Arthritis - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Products under Development by Companies
Systemic Idiopathic Juvenile Arthritis - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Systemic Idiopathic Juvenile Arthritis - Companies Involved in Therapeutics Development
Alteogen Inc
Johnson & Johnson
Livzon Pharmaceutical Group Inc
Mycenax Biotech Inc
Novartis AG
Oncobiologics Inc
Systemic Idiopathic Juvenile Arthritis - Drug Profiles
adalimumab biosimilar - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
adalimumab biosimilar - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
adalimumab biosimilar - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
canakinumab - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
golimumab - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
tocilizumab biosimilar - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
tocilizumab biosimilar - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
tocilizumab biosimilar - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Systemic Idiopathic Juvenile Arthritis - Dormant Projects
Systemic Idiopathic Juvenile Arthritis - Discontinued Products
Systemic Idiopathic Juvenile Arthritis - Product Development Milestones
Featured News & Press Releases
Sep 03, 2013: Novartis receives EU approval for Ilaris in active Systemic Juvenile Idiopathic Arthritis, a serious form of childhood arthritis
Jul 25, 2013: CHMP Adopts Positive Opinion For Novartis's Ilaris
May 10, 2013: Novartis's Ilaris Receives Approval From FDA For Treatment Of Active Systemic Juvenile Idiopathic Arthritis
Dec 19, 2012: Novartis's ACZ885 Significantly Relieves Symptoms In Patients With Serious Form Of Childhood Arthritis In Phase III Trials
Jun 06, 2012: Novartis Announces New Data From Two Trials Of ACZ885 At Annual Congress Of EULAR 2012
Nov 16, 2011: Novartis Study Shows ACZ885 Provides Substantial Symptom Relief In 84% Of Patients With Most Serious Form Of Childhood Arthritis
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
Number of Products under Development for Systemic Idiopathic Juvenile Arthritis, H2 2017
Number of Products under Development by Companies, H2 2017
Products under Development by Companies, H2 2017
Number of Products by Stage and Target, H2 2017
Number of Products by Stage and Mechanism of Action, H2 2017
Number of Products by Stage and Route of Administration, H2 2017
Number of Products by Stage and Molecule Type, H2 2017
Systemic Idiopathic Juvenile Arthritis - Pipeline by Alteogen Inc, H2 2017
Systemic Idiopathic Juvenile Arthritis - Pipeline by Johnson & Johnson, H2 2017
Systemic Idiopathic Juvenile Arthritis - Pipeline by Livzon Pharmaceutical Group Inc, H2 2017
Systemic Idiopathic Juvenile Arthritis - Pipeline by Mycenax Biotech Inc, H2 2017
Systemic Idiopathic Juvenile Arthritis - Pipeline by Novartis AG, H2 2017
Systemic Idiopathic Juvenile Arthritis - Pipeline by Oncobiologics Inc, H2 2017
Systemic Idiopathic Juvenile Arthritis - Dormant Projects, H2 2017
Systemic Idiopathic Juvenile Arthritis - Discontinued Products, H2 2017

List of Figures
Number of Products under Development for Systemic Idiopathic Juvenile Arthritis, H2 2017
Number of Products under Development by Companies, H2 2017
Number of Products by Targets, H2 2017
Number of Products by Stage and Targets, H2 2017
Number of Products by Mechanism of Actions, H2 2017
Number of Products by Stage and Mechanism of Actions, H2 2017
Number of Products by Routes of Administration, H2 2017
Number of Products by Stage and Routes of Administration, H2 2017
Number of Products by Stage and Molecule Types, H2 2017
  • Global Tinea Pedis Treatment Market Size, Status and Forecast 2025
    Published: 13-Apr-2018        Price: US 3300 Onwards        Pages: 112
    This report studies the global Tinea Pedis Treatment market, analyzes and researches the Tinea Pedis Treatment development status and forecast in United States, EU, Japan, China, India and Southeast Asia. This report focuses on the top players in global market, like - GSK - Exeltis USA - Promius Pharma - Valeant - Incyte - Polichem - Viamet Pharmaceuticals - Aqua Pharmaceuticals - Theravance Biopharma - Bristol-Myers Squibb......
  • Global Viscosupplementation Market Size, Status and Forecast 2025
    Published: 05-Apr-2018        Price: US 3300 Onwards        Pages: 93
    This report studies the global Viscosupplementation market, analyzes and researches the Viscosupplementation development status and forecast in United States, EU, Japan, China, India and Southeast Asia. This report focuses on the top players in global market, like - Sanofi - Anika Therapeutics, Inc. - Seikagaku Corporation - Zimmer Holdings Inc - Bioventus - Ferring B.V. - Lifecore Biomedical, LLC - LG Life Sciences Ltd Marke......
  • Global Arthritis Partnering 2012 to 2018
    Published: 01-Apr-2018        Price: US 1995 Onwards        Pages: 200
    "Delivery of this report will take 1-3 days after purchase." Summary The Global Arthritis Partnering Terms and Agreements since 2012 report provides understanding and access to partnering deals and agreements entered into by the world's leading healthcare companies. - Trends in partnering deals - Top deals by value - Deals listed by company A-Z, industry sector, stage of development, technology type The report......
  • Global Rheumatoid Arthritis Partnering 2012 to 2018
    Published: 01-Apr-2018        Price: US 1995 Onwards        Pages: 200
    "Delivery of this report will take 1-3 days after purchase." Summary The Global Rheumatoid Arthritis Partnering Terms and Agreements since 2012 report provides understanding and access to partnering deals and agreements entered into by the world's leading healthcare companies. - Trends in partnering deals - Top deals by value - Deals listed by company A-Z, industry sector, stage of development, technology type ......
  • Global Osteoarthritis Partnering 2012 to 2018
    Published: 01-Apr-2018        Price: US 1995 Onwards        Pages: 100
    "Delivery of this report will take 1-3 days after purchase." Summary The Global Osteoarthritis Partnering Terms and Agreements since 2012 report provides understanding and access to partnering deals and agreements entered into by the world's leading healthcare companies. - Trends in partnering deals - Top deals by value - Deals listed by company A-Z, industry sector, stage of development, technology type The r......
  • Rheumatoid Arthritis Therapeutics in Asia-Pacific Markets to 2023 - Novel JAK and IL-6 Receptor Inhibitors to Stimulate Moderate Growth Despite Launch of Biosimilars of Blockbuster Anti-TNFs
    Published: 01-Mar-2018        Price: US 4995 Onwards        Pages: 148
    Summary Rheumatoid Arthritis (RA) is a chronic, progressive and currently incurable autoimmune disease that primarily affects the joints. It is characterized by synovial inflammation and gradual bone erosion over many years. Disease progression results in stiffness and pain, especially in the hands and feet, which hinders mobility. Without treatment, the disease leads to joint destruction and disability. The chronic nature of the disease, which requires ongoin......
  • Osteoarthritis - Pipeline Review, H1 2018
    Published: 20-Feb-2018        Price: US 2000 Onwards        Pages: 240
    Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Osteoarthritis - Pipeline Review, H1 2018, provides an overview of the Osteoarthritis (Musculoskeletal Disorders) pipeline landscape. Osteoarthritis (OA) is one of the most common forms of arthritis. It is a chronic condition in which the cartilage breaks down. Symptoms of osteoarthritis include sore or stiff joints, pain that is worse after activity, bone spurs and grating sensation. Risk factors ......
  • Systemic Juvenile Idiopathic Arthritis (SJIA) - Global API Manufacturers, Marketed and Phase III Drugs Landscape
    Published: 31-Jan-2018        Price: US 2000 Onwards        Pages: 60
    Introduction DelveInsight's, "Systemic Juvenile Idiopathic Arthritis (SJIA) - Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2018" report provides comprehensive insights about marketed and Phase III products for Systemic Juvenile Idiopathic Arthritis (SJIA) . The report includes information of marketed products including their product description, patent details, forecasted sales till 2020 & API manufacturer details by country. Global API Manufac......
  • Systemic Juvenile Idiopathic Arthritis (SJIA) - Epidemiology Forecast to 2027
    Published: 31-Jan-2018        Price: US 3250 Onwards        Pages: 50
    DelveInsight's "Systemic Juvenile Idiopathic Arthritis (SJIA) - Epidemiology Forecast, 2027" report provides a comprehensive analysis of the Systemic Juvenile Idiopathic Arthritis (SJIA) epidemiology, providing the historical and forecasted data for the 7MM during the forecast period from 2016-2027. Markets Covered - United States - EU5 (Germany, France, Italy, Spain, and the United Kingdom) - Japan Study Period: 2016-2027 Systemi......
  • SERVICES
    Value for Money
    We believe in "optimum utilization of available budget and resources". While servicing our clients' (your) market research requirements, we keep the same approach in focus to help you get the best value for your $$s.
    Ever Growing Inventory
    Ranging from the smallest feasible / required data (datasheets, data facts, SWOT analysis, company profiles, etc) to full research reports that help you make decisions, our inventory is updated almost on a daily basis with the latest industry reports from domain experts that track more than 5000 niche sectors.
    One Stop Solution
    Need a custom research report on medical devices market? Require all available business intelligence on 3D printing industry? Exploring F&B sector of a particular country/region? RnRMarketResearch.com is your one-stop-solution to all market intelligence needs. We not only offer custom research and consulting services, we also "bundle" reports to meet your needs and help you fetch the data analysis you require for your business.
    Dedicated Client Engagement
    Not limited to only "finding" relevant reports for you, our client engagement team dedicates its efforts to understand your "business need" and accordingly maps available research data to help you move forward. Call "your" client engagement executive any time of your day and get your questions answered in order to make the correct business decision.
    Saving Time and Efforts
    Simply share your research requirement details with us and let us do all the hard work to find required intelligence for you. When you add up our "one stop solution" and "dedicated client engagement" services mentioned above, you obviously know the time and effort saving you do by working with us.
    Payment Flexibility
    Working with Fortune 500 organizations, we understand the importance of being flexible for payments. Share your payment terms with us and we will surely match up to them to ensure you get access to required business intelligence data without having to wait for the payment to be done.
    Post-Purchase Research Support
    Have questions after reading a report / datasheet bought through us? Not sure about the methodology used for data available in the research? Talk to us / Share your questions with us and if required, we will connect you with the analyst(s)/author(s) of the report(s) and ensure you get satisfactory answers for the same. Need more data / analysis / report(s) on the topic of your research/project? The RnRMarketResearch.com team is here for you 24X7 to support you with your post-purchase requirements. Subscription Offers & Packages (Get in touch with us for more details - sales@rnrmarketresearch.com / +1 888 391 5441 )
    • Ad Hoc
    • Pay - as - you - go / Bucket Subscriptions
    • Fixed Cost for #of reports
    • Customize / Personalize as per your needs